FDA Inspection
Novartis Gene Therapies, Inc.Novartis Gene Therapies, Inc. – FDA Inspection, Feb 8, 2019
Record Details
This FDA Inspection record concerns Novartis Gene Therapies, Inc., with an inspection on February 8, 2019, issued by the Chicago District Office, covering biologics.
- Office
- Chicago District Office
- People
- Andrew P. Byrnes (Issuing Officer)
- Angela S. Whatley (Issuing Officer)
- Burnell M. Henry (FDA Associated Person)
- Deborah M. Trout (Issuing Officer)
- Wei Wang (Company Rep)
View Company Profile
ID · b459a2fc-1008-4989-8b52-22767733d792
Inspection Facts
- Inspection number
- 1086650
- FDA center
- Biologics
- Outcome
- Form 483 issued
Other FDA inspections of Novartis Gene Therapies, Inc.
1| Date | Classification | Office | Project area |
|---|---|---|---|
| June 16, 2021 | VAI | Center for Biologics Evaluation and Research | Human Cellular, Tissue, and Gene Therapies |
Other documents for Novartis Gene Therapies, Inc.
Document or profile
One record shows the event. A profile shows the pattern.
Buy this document for the source file and details behind this single event.
Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.